Mirati Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$87.7M
Doctors Paid
6,252
Transactions
27,219
2024 Total
$33.7M
Payment Breakdown by Category
Research$85.7M (97.7%)
Food & Beverage$354,651 (0.4%)
Consulting$235,885 (0.3%)
Travel$200,752 (0.2%)
Royalty/License$5,905 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $85.7M | 11,612 | 97.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 441 | 1.2% |
| Food and Beverage | $354,651 | 13,362 | 0.4% |
| Consulting Fee | $235,885 | 147 | 0.3% |
| Travel and Lodging | $200,752 | 440 | 0.2% |
| Honoraria | $125,428 | 61 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $48,695 | 19 | 0.1% |
| Education | $22,555 | 1,135 | 0.0% |
| Royalty or License | $5,905 | 1 | 0.0% |
| Grant | $5,000 | 1 | 0.0% |
Payments by Type
Research
$85.7M
11,612 transactions
General
$2.0M
15,607 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | $33.7M | 0 | 3,560 |
| A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With MTAP Homozygous Deletion | $5.9M | 0 | 1,003 |
| A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy | $5.8M | 1 | 1,481 |
| A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | $5.3M | 0 | 1,113 |
| A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies | $4.1M | 0 | 335 |
| A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination | $3.8M | 0 | 151 |
| A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | $3.2M | 0 | 444 |
| STRATEGIC Alliance Agreement - RCTS#59451 | $3.2M | 0 | 1 |
| A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced | $2.5M | 0 | 23 |
| A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE | $2.4M | 0 | 911 |
| A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib | $2.2M | 0 | 14 |
| Phase 1/2 Study of MRTX0902 in Solid Tumors with Mutations in the KRAS-MAPK Pathway | $1.9M | 0 | 351 |
| A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma | $1.5M | 0 | 183 |
| A Phase 1/1b Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | $1.0M | 0 | 158 |
| A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib | $1.0M | 0 | 7 |
| A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation | $878,730 | 0 | 291 |
| A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 | $814,667 | 0 | 38 |
| A Phase 1, Open-label, Single-dose, Crossover Study to Evaluate the Relative Bioavailability and Food Effect on Adagrasib High Drug Load Tablet | $692,787 | 0 | 1 |
| 902001 SOS1 P1/1b/2 Basket Study | $651,282 | 0 | 223 |
| A Phase 1/1b Trial of MRTX849 in Combination with Palbociclib in Patients with Advanced Solid Tumors with KRAS G12C Mutation | $614,997 | 0 | 63 |
| A Phase 1/2 Trial of MRTX849 in Combination with ABI-009 in Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer with KRAS G12C Mutation | $423,619 | 0 | 27 |
| I-O Sitra Combo MGCD516 - 516002 Nivolumab RCC - A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell | $403,064 | 0 | 1 |
| A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment With Nivolumab in Patients With Advanced Solid Malignancies | $351,996 | 0 | 50 |
| Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | $351,325 | 0 | 4 |
| A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | $341,012 | 0 | 35 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | $330,315 | 0 | 39 |
| A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy S | $315,524 | 0 | 42 |
| 849VS1 Verastem P1/2 Adagrasib + VS-6766 Combo | $240,820 | 0 | 43 |
| A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation | $147,065 | 0 | 12 |
| A phase II trial of sitravatinib plus nivolumab in patients | $122,989 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology & Oncology | $710,974 | 1,875 | $379.19 |
| Medical Oncology | $453,430 | 453 | $1,001 |
| Internal Medicine | $239,027 | 628 | $380.62 |
| Student in an Organized Health Care Education/Training Program | $142,748 | 145 | $984.47 |
| Nurse Practitioner | $114,954 | 488 | $235.56 |
| Family | $40,402 | 756 | $53.44 |
| Medical | $31,016 | 131 | $236.76 |
| Physician Assistant | $30,030 | 332 | $90.45 |
| Critical Care Medicine | $27,696 | 15 | $1,846 |
| Adult Health | $26,029 | 227 | $114.66 |
| Hematology | $25,649 | 187 | $137.16 |
| Specialist | $22,505 | 126 | $178.61 |
| Hospice and Palliative Medicine | $20,078 | 18 | $1,115 |
| Anatomic Pathology & Clinical Pathology | $15,239 | 9 | $1,693 |
| Gerontology | $8,109 | 48 | $168.93 |
| Neurology | $6,831 | 4 | $1,708 |
| Acute Care | $5,526 | 93 | $59.42 |
| Radiation Oncology | $5,322 | 149 | $35.72 |
| Registered Nurse | $5,038 | 90 | $55.97 |
| Cardiovascular Disease | $2,656 | 6 | $442.70 |
| Primary Care | $2,618 | 29 | $90.29 |
| Anatomic Pathology | $2,079 | 1 | $2,079 |
| Family Medicine | $2,050 | 41 | $50.00 |
| Pediatrics | $1,893 | 15 | $126.21 |
| Surgery | $1,627 | 33 | $49.31 |
| Gynecologic Oncology | $1,358 | 23 | $59.04 |
| Diagnostic Radiology | $1,330 | 31 | $42.90 |
| Surgical Oncology | $1,234 | 14 | $88.18 |
| Hospitalist | $1,195 | 17 | $70.27 |
| Oncology | $1,186 | 25 | $47.44 |
| Obstetrics & Gynecology | $759.43 | 15 | $50.63 |
| Pulmonary Disease | $749.91 | 14 | $53.57 |
| Emergency Medicine | $679.06 | 12 | $56.59 |
| Urology | $646.89 | 6 | $107.82 |
| Thoracic Surgery (Cardiothoracic Vascular Surgery) | $531.94 | 9 | $59.10 |
| Nurse Anesthetist, Certified Registered | $489.68 | 7 | $69.95 |
| Psychiatry | $468.17 | 6 | $78.03 |
| Surgical | $465.53 | 16 | $29.10 |
| Dermatology | $409.46 | 5 | $81.89 |
| Anesthesiology | $407.95 | 5 | $81.59 |
| General Practice | $403.25 | 11 | $36.66 |
| Clinical Nurse Specialist | $392.46 | 6 | $65.41 |
| Family Health | $268.56 | 2 | $134.28 |
| Optometrist | $268.04 | 3 | $89.35 |
| Interventional Pain Medicine | $247.76 | 2 | $123.88 |
| Periodontics | $229.36 | 2 | $114.68 |
| Therapeutic Radiology | $213.13 | 6 | $35.52 |
| Infectious Disease | $209.52 | 4 | $52.38 |
| Pediatric Hematology-Oncology | $198.93 | 1 | $198.93 |
| Emergency | $196.36 | 3 | $65.45 |
| Gastroenterology | $184.62 | 5 | $36.92 |
| Allergy & Immunology | $181.75 | 3 | $60.58 |
| Endocrinology, Diabetes & Metabolism | $181.23 | 2 | $90.62 |
| Psychiatric/Mental Health | $173.16 | 3 | $57.72 |
| Geriatric Medicine | $160.83 | 2 | $80.41 |
| Nuclear Imaging & Therapy | $150.30 | 1 | $150.30 |
| Occupational Medicine | $135.52 | 1 | $135.52 |
| Cytopathology | $134.88 | 1 | $134.88 |
| General Acute Care Hospital | $131.92 | 2 | $65.96 |
| Prosthodontics | $124.29 | 1 | $124.29 |
| Women's Health | $121.57 | 4 | $30.39 |
| Pediatric Radiology | $121.53 | 1 | $121.53 |
| Occupational Health | $120.57 | 1 | $120.57 |
| Emergency Medical Services | $111.84 | 2 | $55.92 |
| Legal Medicine | $98.36 | 1 | $98.36 |
| Adult Medicine | $89.96 | 3 | $29.99 |
| Physical Medicine & Rehabilitation | $69.41 | 2 | $34.71 |
| Infusion Therapy | $65.56 | 2 | $32.78 |
| Child & Adolescent Psychiatry | $63.23 | 2 | $31.62 |
| Sports Medicine | $55.18 | 1 | $55.18 |
| Neuroscience | $42.02 | 1 | $42.02 |
| Advanced Practice Midwife | $40.98 | 2 | $20.49 |
| Athletic Trainer | $39.08 | 1 | $39.08 |
| Pain Medicine | $37.72 | 1 | $37.72 |
| Lactation Consultant | $36.12 | 1 | $36.12 |
| Community Health | $35.83 | 2 | $17.92 |
| Neuroradiology | $30.42 | 1 | $30.42 |
| Vascular & Interventional Radiology | $30.42 | 1 | $30.42 |
| Independent Medical Examiner | $29.35 | 1 | $29.35 |
| Hospice | $26.63 | 1 | $26.63 |
| Otolaryngology | $25.91 | 1 | $25.91 |
| Oral and Maxillofacial Pathology | $24.29 | 1 | $24.29 |
| Psychiatric/Mental Health, Adult | $23.57 | 1 | $23.57 |
| Single Specialty | $22.50 | 1 | $22.50 |
| Clinical Pathology | $21.12 | 1 | $21.12 |
| Dentist | $21.01 | 1 | $21.01 |
| Medical-Surgical | $21.00 | 1 | $21.00 |
| Sonography | $20.16 | 1 | $20.16 |
| Procedural Dermatology | $20.13 | 1 | $20.13 |
| Medical Toxicology | $18.87 | 1 | $18.87 |
| Chiropractor | $18.79 | 1 | $18.79 |
| Orthopaedic Surgery | $18.69 | 1 | $18.69 |
| Forensic Pathology | $18.36 | 1 | $18.36 |
| Plastic Surgery | $18.07 | 1 | $18.07 |
| Body Imaging | $14.82 | 1 | $14.82 |
| Neuromuscular Medicine | $14.67 | 1 | $14.67 |
| Obstetrics | $14.38 | 1 | $14.38 |
| Neonatal | $14.29 | 1 | $14.29 |
| Rheumatology | $14.29 | 1 | $14.29 |
| Neuropathology | $13.32 | 1 | $13.32 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Martin Dietrich, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | Rockledge, FL | $132,136 | $0 |
| Dr. Eric Nadler, Md, MD | Medical Oncology | Dallas, TX | $104,584 | $0 |
| Dr. Hatim Husain, Md, MD | Internal Medicine | San Diego, CA | $74,591 | $0 |
| Dr. Edgardo Santos, Md, MD | Hematology & Oncology | Fort Lauderdale, FL | $42,984 | $0 |
| Jewel Johl, M.d, M.D | Hematology & Oncology | Walnut Creek, CA | $41,999 | $0 |
| Miss. Ani Balmanoukian, M.d, M.D | Hematology & Oncology | Baltimore, MD | $40,275 | $0 |
| Ms. Pamela Calarese, Rn Np, RN NP | Nurse Practitioner | Boston, MA | $39,038 | $0 |
| Dr. Mohamed Mohamed, M.d, M.D | Medical Oncology | Greensboro, NC | $38,838 | $0 |
| Dr. Mark Socinski, Md, MD | Hematology & Oncology | Orlando, FL | $38,378 | $0 |
| Michelle Turner, Crnp, CRNP | Nurse Practitioner | Baltimore, MD | $37,940 | $0 |
| Dr. Jason Porter, M.d, M.D | Hematology & Oncology | Germantown, TN | $34,267 | $0 |
| Robert Kratzke, Md, MD | Medical Oncology | Minneapolis, MN | $33,323 | $0 |
| Eugene Muchnik, M.d, M.D | Hematology & Oncology | Williamsport, PA | $30,688 | $0 |
| Tarek Mekhail, M.d, M.D | Hematology & Oncology | Orlando, FL | $30,324 | $0 |
| Dr. Rodolfo Bordoni, Md, MD | Hematology & Oncology | Atlanta, GA | $29,910 | $0 |
| Tracey Evans, Md, MD | Hematology & Oncology | East Norriton, PA | $29,906 | $0 |
| Dr. Suresh Ratnam, Md, MD | Medical Oncology | Mcallen, TX | $29,241 | $0 |
| Dr. Aneel Chowdhary, M.d, M.D | Medical Oncology | Huntington, WV | $28,632 | $0 |
| Dr. Sujith Kalmadi, Md, MD | Hematology & Oncology | Chandler, AZ | $26,842 | $0 |
| Sarah Sagorsky, Pa-C, PA-C | Medical | Baltimore, MD | $24,191 | $0 |
| Dr. Vikas Dembla, M.d, M.D | Internal Medicine | Spartanburg, SC | $23,415 | $0 |
| Dr. Misako Nagasaka, Md, MD | Hematology & Oncology | Orange, CA | $22,409 | $0 |
| Dr. Michael Kosty, M.d, M.D | Hematology & Oncology | La Jolla, CA | $22,032 | $0 |
| Alejandro Calvo, Md, MD | Hematology & Oncology | Kettering, OH | $21,887 | $0 |
| Dr. Johann Brandes, Md, Phd, MD, PHD | Critical Care Medicine | Murfreesboro, TN | $20,946 | $0 |
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. has made $87.7M in payments to 6,252 healthcare providers, recorded across 27,219 transactions in the CMS Open Payments database. In 2024, the company paid $33.7M. The top product by payment volume is KRAZATI ($61.5M).
Payments were distributed across 100 medical specialties. The top specialty by payment amount is Hematology & Oncology ($710,974 to 1,875 doctors).
Payment categories include: Food & Beverage ($354,651), Consulting ($235,885), Research ($85.7M), Travel & Lodging ($200,752), Royalties ($5,905).
Mirati Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.